May 24, 2020 - May 24, 2022
Public Summary
This is a study to test whether favipiravir, an oral pill that has broad antiviral activity, may be effective at reducing the symptoms of COVID-19 if given early to patients (similar to how Tamiflu is given early for the flu to help shorten the duration of the illness). Participants will receive either treatment pill or placebo pill to be taken twice a day for 10 days and then followed closely for a month.
Type of Research: Clinical trial
Topics: Antibody, Applied Research, Immunology, Host Response, Host Factors, Mental Health, Psychology, Co-Morbidities, Hidradentis Supporativa, Gastroesophageal Reflux Disease (GERD), Clinical Trial, Clinical Presentation of Infection, Biomarkers, Health Disparities, Epidemiology, Transmission, Aerosol, Risk Factors, Incidence, Clinical Outcome, Clinical History, Computational Analysis, Diagnostics, Viral Detection, Antibody Detection, Diagnostic Efficacy, Diagnostic Reliability, Diagnostic Scalability, Treatments, Drug Development, Drug Repurposing, Drug Targets, Drug Treatment, Drugs, Virology, Viral Interactome, Viral Proteins, Virus Biology, Virus Evolution, Virus Factors